PPARA and myocardial infarction: In our results, clopidogrel users who were homozygous carriers of a PPAR-α minor allele and were statin/fibrate users had a significant 26 unit decrease in PRU (Table 2), implicating that this group of patients may have a 10% decreased risk of the composite of death, myocardial infarction, or stent thrombosis compared to the patients with heterozygous and wild-type PPAR-α genotypes.